

The GSK - Pfizer Multibillion Dollar Global Vaccine Monopoly

Big Money For Big Pharma

By <u>Prof Michel Chossudovsky</u> Global Research, January 05, 2021

It's Big Pharma, It's Big Money. It's the multibillion dollar global vaccine market.

In August 2019, five months before the onslaught of the Covid-19 crisis, two of the largest Worldwide Pharma conglomerates decided to join hands in a strategic relationship which barely made the headlines.

In an August 2019 Press release GSK confirmed the formation of a major partnership with Pfizer entitled <u>the Consumer Health Joint Venture</u>:

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has completed its transaction with Pfizer to combine their consumer healthcare businesses into a world-leading Joint Venture.

While emphasizing that the relationship is limited to "trusted consumer health brands", the agreement is nonetheless far-reaching. It includes financial procedures as well as possible joint multibillion dollar investment projects.

While it does not constitute a merger, the GSK report points to selective integration (implying de facto collusion) in areas of marketing and distribution:


... the Joint Venture [GSK-Pfizer] will focus on completing the integration [in consumer health products] of the two businesses, which is expected to realise annual cost savings of £0.5bn by 2022 for expected total cash costs of £0.9 billion and non-cash charges of £0.3 billion. Up to 25% of the cost savings are intended to be reinvested in the business to support innovation and other growth opportunities.

The Vaccine Market

At present, five multinational companies including GSK and Pfizer control 80% of the global vaccine market. Under the agreement between the two companies, GSK-Pfizer is slated to play a dominant and coordinated role in regards to the Covid-19 vaccine.

Top 10 Vaccine Companies

Based on Global Revenues in 2017 and 2024 (USD Millions)



Source Pharma Boardroom

This GSK-Pfizer relationship also encompasses a network of partner pharmaceutical companies, research labs, virology institutes, military and biotech entities, etc. many of which are currently involved in the Covid vaccine initiative.

Covid Vaccine Financed by Soaring Public Debt

The Covid vaccine is a multibillion dollar operation which will contribute to increasing the public debt of more than 150 national governments.

Supported by the fear campaign, Money rather than Public Health is the driving force behind this initiative:

"The completion of the joint venture with Pfizer marks the beginning of the next phase of our transformation of GSK. This is an important moment for the Group, laying the foundation for two great companies, one in Pharmaceuticals and Vaccines and one in Consumer Health." (<u>GSK</u>, August 1, 2019, emphasis added) While the two companies had envisaged a "separation" clause following a process of restructuring, GSK and Pfizer have nonetheless integrated their decision making, specifically with regards to the vaccine market:

"With our future intention to separate, the transaction also presents a clear pathway forward for GSK to create a new global Pharmaceuticals/Vaccines company, with an R&D approach focused on science related to the immune system, use of genetics and advanced technologies, ... Ultimately, our goal is to create two exceptional, UK-based global companies, with appropriate capital structures" (GSK)

What is at stake is the de facto formation of a Big Pharma Worldwide monopoly with a global network of "partners".

Most of the so-called 125 ("small pharma") candidates are involved in subcontracting (outsourcing) manufacturing and marketing activities on behalf of the Big Pharma conglomerates.

The COVAX Initiative and Big Pharma

The COVAX initiative launched in April 2020 was intended to facilitate the Worldwide distribution of the Covid vaccine. It is coordinated by the Coalition for Epidemic Preparedness Innovations (CEPI), GAVI, the Vaccine Alliance, and the World Health Organization (WHO) (all of which are partially funded by the Gates foundation).

In turn, the Gates foundation is a major shareholder of the Big Pharma vaccine conglomerates including GSK and Pfizer:

Sanofi and Glaxosmithkline were awarded about \$2.1 billion in July from the U.S. Operation Warp Speed to support development and large-scale manufacturing of their adjuvanted recombinant protein subunit vaccine, providing the federal government with 100 million doses. The companies also have supply deals with the U.K., Canada and Gavi, an international vaccine alliance. (BioWorld, December 2020, emphasis added)


The GSK-Pfizer joint venture alliance is being used to extend their control over vaccine sales and production in all major regions of the World including China and Latin America, through a nexus of corporate and scientific partnerships.

Other major actors are France's Sanofi which acts in partnership with GSK, Moderna which has ties to Pfizer, Merck, Astrazeneca and Johnson and Johnson.

The November 2020 Launching of the Covid Vaccine

Were the standard animal lab tests using mice or ferrets conducted?

Or did Pfizer, Moderna <u>"go straight to human "guinea pigs."</u>? Human tests began in late July and early August. "Three months is unheard of for testing a new vaccine. <u>Several years is</u> <u>the norm</u>."



Our thanks to Large and JIPÉM

This caricature by Large + JIPÉM explains our predicament:

Mouse No 1: "Are You Going to get Vaccinated",

Mouse No. 2: Are You Crazy, They Haven't finished the Tests on Humans"

And why do we need a vaccine for Covid-19 when both the WHO and the US Center for Disease Control and Prevention (CDC) have confirmed unequivocally that Covid-19 is "similar to seasonal influenza".

The unspoken answer is "Big Money".

Biggest Vaccine Operation in World History

The plan to develop the Covid-19 vaccine is profit driven. It is supported by corrupt governments serving the interests of Big Pharma.

The US government had already ordered 100 million doses back in July 2020 and the EU is to purchase 300 million doses. It's Big Money for Big Pharma, generous payoffs to corrupt politicians, at the expense of tax payers.

The objective is ultimately to make money, by vaccinating the entire planet of 7.8 billion people for SARS-CoV-2.

The Covid vaccine in some cases envisages more than one shot. If this plan were to go ahead as planned, it would be the largest vaccine initiative in World history and the biggest money making operation for Big Pharma.

Moreover, under the Pfizer Moderna initiative, the mRNA vaccine will have an impact on the human genome.

The ID2020 Digital Vaccine Identity Platform

And there is also the project promoted by GAVI to insert a "digital passport".

It's called the ID2020 Agenda, which, <u>according to Peter Koenig</u> constitutes "an electronic ID program that uses generalized vaccination as a platform for digital identity".

"The program harnesses existing birth registration and vaccination operations to provide newborns with a portable and persistent biometrically-linked digital identity". (Peter Koenig, March 2020)

The Founding Partners of ID2020 are Microsoft, the Rockefeller Foundation and the Global Alliance for Vaccines and Immunization (GAVI) among others.

It is worth noting the timeline: The ID2020 Alliance held their Summit in New York, entitled "Rising to the Good ID Challenge", on September 19, 2019, exactly one month prior to nCov-2019 simulation exercise entitled Event 201 at John Hopkins in New York:

Is it just a coincidence that ID2020 is being rolled out at the onset of what the WHO calls a Pandemic? – Or is a pandemic needed to 'roll out' the multiple devastating programs of ID2020? (Peter Koenig, March 2020)

ID2020 is part of a "World Governance" project which, if applied, would roll out the contours of what some analysts have described as a Global Police State embedding through vaccination the personal details of several billion people Worldwide.

The original source of this article is Global Research Copyright © <u>Prof Michel Chossudovsky</u>, Global Research, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Prof Michel Chossudovsky

About the author:

Michel Chossudovsky is an award-winning author, Professor of Economics (emeritus) at the University of Ottawa, Founder and Director of the Centre for Research on Globalization (CRG), Montreal, Editor of Global Research. He has taught as visiting professor in Western Europe, Southeast Asia, the Pacific and Latin America. He has served as economic adviser to governments of developing countries and has acted as a consultant for several international organizations. He is the author of 13 books. He is a contributor to the Encyclopaedia Britannica. His writings have been published in more than twenty languages. In 2014, he was awarded the Gold Medal for Merit of the Republic of Serbia for his writings on NATO's war of aggression against Yugoslavia. He can be reached at crgeditor@yahoo.com

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca